<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A total of 68 adult patients with B-cell <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (<z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e>) were treated in three consecutive adult multicenter ALL studies </plain></SENT>
<SENT sid="1" pm="."><plain>The diagnosis of <z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e> was confirmed by L3 <z:mp ids='MP_0000002'>morphology</z:mp> and/or by surface immunoglobulin (Slg) expression with &gt; 25% blast cell infiltration in the bone marrow (BM) </plain></SENT>
<SENT sid="2" pm="."><plain>They were characterized by male predominance (78%) and a median age of 34 years (15 to 65 y) with only 9% adolescents (15 to 20 y), but 28% elderly patients (50 to 65 y) </plain></SENT>
<SENT sid="3" pm="."><plain>The patients received either a conventional (N = 9) ALL treatment regimen (ALL study 01/81) or protocols adapted from childhood <z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e> with six short, intensive 5-day cycles, alternately A and B </plain></SENT>
<SENT sid="4" pm="."><plain>In study B-NHL83 (N = 24) cycle A consisted of fractionated doses of <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> 200 mg/m2 for 5 days, intermediate-dose <z:chebi fb="0" ids="44185">methotrexate</z:chebi> (IdM) 500 mg/m2 (24 hours), in addition to <z:chebi fb="0" ids="28680">cytarabine</z:chebi> (AraC), teniposide (VM26) and <z:chebi fb="0" ids="8382">prednisone</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>Cycle B was similar except that AraC and VM26 were replaced by <z:chebi fb="0" ids="28748">doxorubicin</z:chebi> </plain></SENT>
<SENT sid="6" pm="."><plain>Major changes in study B-NHL86 (N = 35) were replacement of <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> by ifosphamide 800 mg/m2 for 5 days, an increase of IdM to high-dose, 1,500 mg/m2 (HdM) and the addition of <z:chebi fb="0" ids="28445">vincristine</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain>A cytoreductive pretreatment with <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> 200 mg/m2, and <z:chebi fb="0" ids="8382">prednisone</z:chebi> 60 mg/m2, each for 5 days was recommended in study B-NHL83 for patients with high white blood cell (WBC) count (&gt; 2,500/m2) or large <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> burden and was obligatory for <z:hpo ids='HP_0000001'>all</z:hpo> patients in study B-NHL86 </plain></SENT>
<SENT sid="8" pm="."><plain>Central <z:mp ids='MP_0008912'>nervous</z:mp> system (<z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi>) prophylaxis/treatment consisted of intrathecal <z:chebi fb="0" ids="44185">methotrexate</z:chebi> (MTX) therapy, later extended to the triple combination of MTX, AraC, and <z:chebi fb="0" ids="41879">dexamethasone</z:chebi>, and a <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> irradiation (24 Gy) after the second cycle </plain></SENT>
<SENT sid="9" pm="."><plain>Compared with the ALL 01/81 study where <z:hpo ids='HP_0000001'>all</z:hpo> the patients died, results obtained with the pediatric protocols B-NHL83 and B-NHL86 were greatly improved </plain></SENT>
<SENT sid="10" pm="."><plain>The complete remission (CR) rates increased from 44% to 63% and 74%, the probability of <z:hpo ids='HP_0001909'>leukemia</z:hpo> free survival (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LFS</z:e>) from 0% to 50% and 71% (P = .04), and the overall survival rates from 0% to 49% and 51% (P = .001) </plain></SENT>
<SENT sid="11" pm="."><plain>Toxicity, mostly hematotoxicity and mucositis, was severe but manageable </plain></SENT>
<SENT sid="12" pm="."><plain>In both studies B-NHL83 and B-NHL86, almost <z:hpo ids='HP_0000001'>all</z:hpo> relapses occurred within 1 year </plain></SENT>
<SENT sid="13" pm="."><plain>The time to relapse was different for BM, 92 days, and for isolated <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> and combined BM and <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> relapses, 190 days (P = .08) </plain></SENT>
<SENT sid="14" pm="."><plain>The overall <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> relapses changed from 50% to 57% and 17%, most probably attributable to the high-dose MTX and the triple intrathecal therapy </plain></SENT>
<SENT sid="15" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LFS</z:e> in studies B-NHL83 and B-NHL86 was significantly influenced by the initial WBC count &lt; or &gt; 50,000/microL, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LFS</z:e> 71% versus 29% (P = .003) and <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> value &gt; or &lt; 8 g/dL, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LFS</z:e> 67% versus 27% (P = .02) </plain></SENT>
<SENT sid="16" pm="."><plain>Initial <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> involvement had no adverse impact on the outcome </plain></SENT>
<SENT sid="17" pm="."><plain>Elderly <z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e> patients (&gt; 50 years) also benefited from this treatment with a CR rate of 56% and a <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LFS</z:e> of 56% </plain></SENT>
<SENT sid="18" pm="."><plain>It is concluded that this short intensive therapy with six cycles is effective in adult <z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e> </plain></SENT>
<SENT sid="19" pm="."><plain>HdM and fractionated higher doses of <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> or ifosphamide seem the two major components of treatment </plain></SENT>
</text></document>